Case No. | Anti-GABA-B receptor antibodies | Other antibodies | CSF routine | Treatment | Follow-up period (months) | Outcomes | Initial mRS on admission | Follow-up mRS | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Serum | CSF | Serum | CSF | WBC (× 106/L) | Protein (g/L) | ICU | Latency to immuno-therapy (days) | Immunotherapy | Antiepileptic therapy | |||||
Favorable-prognosis group | ||||||||||||||
1 | + | + | – | – | 8 | 0.36 | + | 70 | MP | LEV | 18 | Cured | 5 | 0 |
2 (primary) | ++ | ++ | – | – | 18 | 0.57 | + | 30 | IVIG | LEV | ||||
2 (recurrence) | + | + | – | – | 18 | 0.74 | – | 7 | IVIG+MP | – | 17 | Improved | 4 | 1 |
3 | + | + | – | – | 5 | 0.43 | – | 30 | IVIG+MP | – | 2 | Improved | 5 | 1 |
4 | +++ | +++ | – | – | 103 | 0.53 | – | 16 | MP | – | 27 | Improved | 2 | 1 |
5 | ++ | ++ | – | – | 42 | 0.39 | + | 18 | IVIG | OXC | 20 | Cured | 5 | 0 |
6 | + | + | – | – | 4 | 0.44 | – | 15 | IVIG+MP | VPA + LEV | 8 | Improved | 2 | 1 |
7 | + | + | – | – | 19 | 0.34 | – | 22 | IVIG | – | 5 | Cured | 2 | 0 |
8 | + | + | – | NMDAR+ | 7 | 0.39 | – | – | – | – | 3 | Improved | 4 | 1 |
9 | + | + | – | – | 8 | 0.33 | – | 35 | MP | CBZ | 3 | Improved | 5 | 1 |
10 | + | + | – | – | 34 | 1.09 | – | 17 | IVIG | – | 2 | Improved | 2 | 1 |
11 (primary) | ++ | + | – | – | 20 | 0 | + | 29 | MP | OXC | ||||
11 (recurrence) | + | + | – | – | 6 | 0.24 | – | – | LEV | 27 | Cured | 3 | 0 | |
Poor-prognosis group | ||||||||||||||
12 | + | + | Hu+ | – | 43 | 0.39 | + | 15 | IVIG | LEV | 9 | Death | 4 | 6 |
13 (primary) | +~++ | +~++ | CV2/CRMP5++ | CV2/CRMP5+++ | 9 | 0.63 | + | 15 | IVIG+MP | LEV | ||||
13 (recurrence) | + | + | CV2/CRMP5+ | CV2/CRMP5+ | 9 | 0.63 | + | 8 | IVIG+MP | – | 13 | Death | 5 | 6 |
14 | +++ | +++ | Hu+ | Hu+ | 96 | 0.37 | + | – | – | – | 27 | Death | 5 | 6 |
15 | +++ | ++ | – | – | 7 | 0.37 | + | 12 | IVIG+MP | OXC | 25 | Death | 5 | 6 |
16 | + | + | – | – | 13 | 0.39 | + | – | – | – | 12 | Death | 5 | 6 |
17 | ++ | ++ | – | – | 21 | 0.49 | + | 13 | IVIG+MP | LEV | 20 | Death | 5 | 6 |
18 | + | + | – | – | 13 | 0.29 | + | – | – | LEV | 3 | Death | 5 | 6 |
19 | + | + | – | – | 31 | 0 | + | 5 | IVIG+MP | OXC | 9 | Unchanged | 5 | 5 |